Biocon Biologics And Civica Partner To Expand Access To Insulin Aspart In The US

Biocon Biologics Ltd. and Civica, Inc. have announced a strategic collaboration to improve access and affordability of Insulin Aspart in the United States.

The partnership aims to address the growing need for affordable insulin amid rising diabetes rates, with Biocon Biologics supplying Insulin Aspart drug substance and Civica producing the finished drug product at its Petersburg, Va., facility.

The initiative comes as insulin costs remain a significant challenge for patients. According to Civica CEO Ned McCoy, affordability is a critical issue, with one in five people with diabetes having skipped, delayed, or used less insulin than needed due to financial constraints.

“Civicas mission is to help people who need access to necessary generic and biosimilar medicines at affordable prices,” McCoy said. “This partnership with Biocon Biologics will allow us to provide patients with Insulin Aspart through our U.S.-based manufacturing operations.”

Biocon Biologics CEO Shreehas Tambe emphasized the companys commitment to expanding patient access to high-quality biosimilars.

“As a fully integrated global biologics company, Biocon Biologics is uniquely positioned to drive commercial success through tailored go-to-market strategies that create lasting value for all stakeholders,” Tambe said. “Our collaboration with Civica reflects this commitment, enabling us to expand patient access to Insulin Aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes.”

This agreement is separate from Biocon Biologics own Insulin Aspart drug product, which is currently under U.S. Food and Drug Administration (FDA) review.

With 38.4 million people in the U.S. living with diabetes — 11.6% of the population, according to the CDC — the demand for affordable insulin is greater than ever. An additional 97.6 million Americans have been identified as prediabetic, highlighting the urgent need for cost-effective treatment options.

Biocon Biologics Ltd. is a fully integrated global biosimilars company focused on affordable healthcare solutions. The company has commercialized nine biosimilars across 120+ countries, with a pipeline targeting diabetology, oncology, immunology, and ophthalmology.

Civica, Inc., a non-profit pharmaceutical company, was founded in 2018 to address persistent drug shortages. Its Petersburg, Va., facility is designed to produce prefilled insulin pens and vials, ensuring a stable and affordable supply for patients in need.